Characteristics of a multigene assay (MammaPrint/Blueprint) to predict early recurrence of hormone receptor-positive, HER2-negative breast cancer: a case‒control study (WJOG16722B)
Compared with patients without recurrence, those with early recurrence showed a significantly higher prevalence of high-risk MP results and Luminal B BP subtype. High-risk MP/Luminal B BP subtype suggested an association with early recurrence in patients with HR + /HER2- early breast cancer.
Authors
- Mami Iida (ORCID: https://orcid.org/0000-0001-6803-4483)
- Akemi Kataoka
- T. Ikeno
- Tsutomu Kawaguchi (ORCID: https://orcid.org/0000-0001-6182-9005)
- Masashi Wakabayashi (ORCID: https://orcid.org/0009-0001-6368-5671)
- Natsue Uehiro (ORCID: https://orcid.org/0000-0002-6940-448X)
- Rurina Watanuki (ORCID: https://orcid.org/0000-0002-7462-4137)
- Hidenori Kamio
- Yuri Kimura (ORCID: https://orcid.org/0000-0002-3457-9378)
- H. Sakai
- Toshimi Takano
- Atsushi Yoshida
- Junji Tsurutani
- Atsushi Fushimi
- Yukinori Ozaki
Institutions
- Jikei University School of Medicine (JP)
- SHOWA Medical University (JP)
- Tokyo Metropolitan Komagome Hospital (JP)
- St. Luke's International Hospital (JP)
- Eli Lilly (Japan) (JP)
- National Cancer Center Hospital East (JP)
- Japanese Foundation For Cancer Research (JP)
Publication Details
- Journal
- Breast Cancer
- Published
- 2026-03-26
- DOI
- https://doi.org/10.1007/s12282-026-01847-2
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00